Q32 Bio
QTTB
80 hedge funds and large institutions have $569M invested in Q32 Bio in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 20 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
0.14% more ownership
Funds ownership: 3.83% → 3.97% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $588M → $569M (-$18.9M)
7% less funds holding
Funds holding: 86 → 80 (-6)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13M |
| 3 |
RI
RTW Investments
New York
|
+$7.45M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.74M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$22.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.11M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$4.07M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$1.96M |
QTTB Hedge Fund Activity: Q3 2019 in Review
80 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q3 2019, worth a combined $569M — down 3.2% from $588M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of QTTB and 14 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 35 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $17.9M. The largest seller was Vivo Capital, exiting entirely with an estimated $22.7M sold.
- 80 institutional investors held Q32 Bio (QTTB) as of Q3 2019, down from 86 in Q2 2019.
- Funds reported $569M of Q32 Bio stock for Q3 2019, down 3.2% quarter-over-quarter.
- 14 funds opened new Q32 Bio positions in Q3 2019 and 20 closed out, a net change of -6 holders.
- The largest Q32 Bio buyer in Q3 2019 was T. Rowe Price Associates, an estimated $17.9M added.
- The largest Q32 Bio seller in Q3 2019 was Vivo Capital, an estimated $22.7M sold.
Based on aggregated 13F filings for Q3 2019.